| Literature DB >> 32549097 |
Marcin Szczechowicz1, Alexander Weymann1, Sabreen Mkalaluh1, Ahmed Mashhour1, Konstantin Zhigalov1, Jerry Easo1.
Abstract
OBJECTIVE: To analyze patients' preoperative characteristics, surgical data, postoperative courses, and short- and long-term outcomes after implantation of different full-root prostheses for destructive aortic valve endocarditis.Entities:
Keywords: Allografts; Aortic Valve; Endocarditis, Bacterial; Heterografts; Reoperation; Stents; Transplantation, Heterologous
Year: 2020 PMID: 32549097 PMCID: PMC7299601 DOI: 10.21470/1678-9741-2020-0020
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Analyzed options for aortic root replacement (in the middle) due to destructive endocarditis. A) Stentless porcine xenograft, B) biological valve conduit, C) homograft, D) mechanical valve conduit.
Preoperative characteristics and comorbidities.
| Characteristics | Freestyle | Other biological conduit | Homograft | Mechanical conduit | |
|---|---|---|---|---|---|
| N | 53 (66.25%) | 13 (16.25%) | 9 (11.25%) | 5 (6.25%) | - |
| Females | 7 (13.2%) | 1 (7.7%) | 3 (33.3%) | 0 | 0.248 |
| Age (years) | 70 (62 to 75) | 55 (45 to 68) | 66 (46 to 70) | 55 (48 to 58) | 0.124 |
| Ejection fraction | 60 (55 to 65) | 55 (38 to 63) | 65 (60 to 67) | 55 (35 to 73) | 0.178 |
| Previous heart surgery | 33 (62.3%) | 8 (61.5%) | 8 (88.9%) | 3 (60%) | 0.465 |
| Aortic valve surgery | 31 (58.5%) | 8 (61.5%) | 7 (77.8%) | 3 (60%) | 0.751 |
| Mechanical aortic valve prosthesis | 11 (20.8%) | 4 (30.8%) | 5 (55.6%) | 2 (40%) | 0.156 |
| Mechanical aortic valve conduit | 2 (3.8%) | 2 (15.4%) | 2 (2.2%) | 0 | 0.477 |
| Biological aortic valve prosthesis | 20 (37.7%) | 4 (30.8%) | 2 (22.2%) | 1 (20%) | 0.709 |
| Biological aortic root prosthesis | 4 (7.5%) | 2 (15.4%) | 1 (11.1%) | 0 | 0.716 |
| Coronary artery bypass grafting | 7 (13.2%) | 1 (7.7%) | 2 (22.2%) | 0 | 0.617 |
| Relevant coronary artery disease | 12 (22.6%) | 2 (15.4%) | 2 (22.2%) | 0 | 0.641 |
| Atrial fibrillation | 9 (17%) | 0 | 0 | 2 (20%) | 0.076 |
| Arterial hypertension | 25 (47.2%) | 7 (53.8%) | 3 (33.3%) | 1 (20%) | 0.518 |
| Chronic kidney disease | 13 (24.5%) | 4 (30.8%) | 3 (33.3%) | 3 (60%) | 0.397 |
| Diabetes mellitus | 3 (5.7%) | 4 (30.8%) | 0 | 0 | 0.020 |
| Additive EuroSCORE | 19 (17 to 22) | 19 (16 to 20) | 19 (17 to 21) | 18 (17 to 20) | 0.284 |
EuroSCORE = European System for Cardiac Operative Risk Evaluation
Surgical data.
| Characteristics | Freestyle | Other biological conduit | Homograft | Mechanical conduit | |
|---|---|---|---|---|---|
| N | 53 (66.25%) | 13 (16.25%) | 9 (11.25%) | 5 (6.25%) | - |
| Surgery time (min) | 265 (195 to 343) | 322 (225 to 478) | 398 (245 to 473) | 305 (202 to 464) | 0.086 |
| Cardiopulmonary bypass time (min) | 164 (121 to 229) | 210 (114 to 289) | 225 (150 to 341) | 199 (131 to 316) | 0.157 |
| Cross-clamp time (min) | 114 (85 to 140) | 134 (87 to 146) | 146 (114 to 198) | 128 (101 to 149) | 0.137 |
| Aortic anulus diameter (mm) | 25 (25 to 27) | 25 (25 to 29) | 23 (23 to 27) | 27 (23 to 29) | 0.396 |
| Periannular complications | |||||
| Fistula | 4 (7.5%) | 1 (7.7%) | 2 (22.2%) | 2 (40%) | 0.106 |
| Abscess | 23 (43.3%) | 6 (46.2%) | 6 (66.7%) | 2 (40%) | 0.623 |
| Aortoventricular dehiscence | 12 (22.6%) | 3 (23.1%) | 3 (33.3%) | 2 (40%) | 0.773 |
| Chronic type-A aortic dissection | 1 (1.9%) | 0 | 1 (11.1%) | 0 | 0.350 |
| Inflammatory aneurysm of the aortic root | 2 (3.8%) | 0 | 1 (11.1%) | 2 (40%) | 0.009 |
| Concomitant procedures | 25 (47.2%) | 6 (46.2%) | 8 (88.9%) | 3 (60%) | 0.127 |
| Mitral valve surgery | 7 (13.2%) | 1 (7.7%) | 4 (44.4%) | 2 (40%) | 0.050 |
| Replacement of the ascending aorta | 11 (20.8%) | 0 | 4 (44.4%) | 0 | 0.042 |
| Coronary artery bypass grafting | 8 (15.1%) | 6 (46.2%) | 2 (22.2%) | 1 (20%) | 0.110 |
| Bail-out bypass | 3 (5.7%) | 4 (30.8%) | 1(11.1%) | 1 (20%) | 0.072 |
| Circulatory support | |||||
| Extracorporeal membrane oxygenation | 3 (5.7%) | 0 | 0 | 1 (20%) | 0.311 |
| Intra-aortic balloon pump | 7 (%) | 3 (%) | 0 | 1 (20%) | 0.463 |
Postoperative characteristics.
| Characteristics | Freestyle | Other biological conduit | Homograft | Mechanical conduit | |
|---|---|---|---|---|---|
| N | 53 (66.25%) | 13 (16.25%) | 9 (11.25%) | 5 (6.25%) | - |
| Acute kidney injury | 10 (18.9%) | 4 (30.8%) | 1 (11.1%) | 1 (20%) | 0.699 |
| Temporary dialysis | 3 (5.7%) | 1 (7.7%) | 0 | 0 | 0.805 |
| Atrial fibrillation | 12 (22.6%) | 5 (38.5%) | 1 (11.1%) | 0 | 0.259 |
| Revision due to mediastinal bleeding | 7 (13.2%) | 4 (30.8%) | 0 | 2 (40%) | 0.103 |
| Inferior pericardiotomy due to pericardial tamponade | 3 (5.7%) | 1 (7.7%) | 0 | 1 (20%) | 0.514 |
| Delirium | 5 (9.4%) | 0 | 0 | 0 | 0.437 |
| Stroke | 1 (1.9%) | 1 (7.7%) | 0 | 0 | 0.598 |
| Respiratory failure | 17 (32.1%) | 4 (30.8%) | 0 | 1 (20%) | 0.243 |
| Cardiopulmonary resuscitation | 0 | 1 (7.7%) | 1 (11.1%) | 0 | 0.129 |
| Low output syndrome | 3 (5.7%) | 0 | 0 | 1 (20%) | 0.311 |
| Pacemaker implantation | 7 (13.2%) | 1 (7.7%) | 0 | 0 | 0.524 |
| Packed red cells transfusion (ml) | 1200 (600 to 3000) | 2700 (600 to 10275) | 2400 (800 to 4200) | 600 (0 to 3000) | 0.280 |
| Fresh frozen plasma transfusion (ml) | 900 (0 to 2250) | 2400 (600 to 9600) | 500 (0 to 2050) | 0 (0 to 2400) | 0.088 |
| Mechanical ventilation (hours) | 14 (2 to 74) | 22 (14 to 105) | 18 (8 to 90) | 30 (24 to 30) | 0.384 |
| Intensive care unit length of stay (days) | 3 (2 to 10) | 3 (1 to 8) | 3 (2 to 14) | 2 (1 to 16) | 0.658 |
| Hospital length of stay (days) | 10 (6 to 17) | 9 (4 to 12) | 7 (7 to 23) | 8 (3 to 19) | 0.620 |
Follow-up data.
| Characteristics | Freestyle | Other biological conduit | Homograft | Mechanical conduit | |
|---|---|---|---|---|---|
| N | 53 (66.25%) | 13 (16.25%) | 9 (11.25%) | 5 (6.25%) | - |
| 30-day mortality | 8 (15.1%) | 5 (38.5%) | 2 (22.2%) | 3 (60%) | 0.055 |
| Mean survival with 95% confidence interval (years) | 8.1 (6.2 to 9.9) | 2.8 (1.1 to 4.4) | 13.7 (8.9 to 18.5) | 1.4 (0 to 3) | 0.014 |
| Aortic valve redo-surgery within the follow-up, absolute values | 1 (1.9%) | 2 (15.4%) | 3 (33.3%) | 0 | 0.005 |
| Aortic valve redo-surgery within the follow-up (events/100 patient-years) | 0.4 | 8 | 4.3 | 0 | < 0.001 |
| Mean freedom from composite endpoint (death, stroke, aortic valve redo surgery) with 95% confidence interval (years) | 7.6 (5.8 to 9.5) | 2.1 (0.6 to 3.7) | 11.3 (6.3 to 16.4) | 1.4 (0 to 3) | 0.011 |
| Incidence of composite endpoint within the follow-up (death, stroke, aortic valve redo surgery) (events/100 patient-years) | 10.8 | 44.4 | 7.4 | 82.5 | < 0.001 |
Fig. 2Survival curves for all four analyzed groups.
Fig. 3Cumulative freedom from composite endpoint for all four surgical options.
| Abbreviations, acronyms & symbols | |
|---|---|
| Authors' roles & responsibilities | |
|---|---|
| MS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| AW | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| SM | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| AM | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| KZ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| JE | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |